Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207408 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
A Phase 2 study of Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis, sponsored by Dynavax Technologies Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 3
- Study locations
NCT07207408 is a Phase 2 study of Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis that is actively recruiting participants, run by Dynavax Technologies Corporation. The registered enrollment target is 148 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07207408, a Phase 2 study of Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis, is actively recruiting participants, sponsored by Dynavax Technologies Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
Conditions Studied
Interventions
- BIOLOGICAL rF1V-1018
Study Locations (3)
Florida
- AMR- Miami - Miami
Kansas
- AMR- El Dorado - El Dorado
Nevada
- AMR- Las Vegas - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2026-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07207408
The ClinicalTrials.gov registry entry for NCT07207408 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis appearing as the primary indexed condition, and to 1 intervention - of which rF1V-1018 is the first listed.
NCT07207408 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Kansas, Nevada.
Frequently Asked Questions
What is clinical trial NCT07207408 about?
NCT07207408 is a clinical study titled "Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age". This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
What is the current status of trial NCT07207408?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2025-09-11. Estimated completion is 2026-10-16.
What conditions does trial NCT07207408 study?
This clinical trial studies the following conditions: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis.
What interventions are being tested in trial NCT07207408?
The interventions under investigation include: rF1V-1018 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07207408?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207408 being conducted?
This trial has 3 study locations across Florida, Kansas, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.